Pharmacy and Therapeutics Committee Meeting Update

At the December 13, 2021 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed the medications below and decided the following:

Name & Indication
Decision
Orladeyo (berotralstat) – Indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. Premium and Value formularies:
Non-preferred specialty brand with prior authorization

Core NH formulary:
Remain Non-Formulary

Medicare Advantage formulary:
Remain Non-Formulary

Lupkynis (voclosporin) – Indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). Premium and Value formularies:
Remain Non-Formulary

Core NH formulary:
Remain Non-Formulary

Medicare Advantage formulary:
Remain Non-Formulary


Publication Information

Audrey Kleinberg,
Director, Provider Relations & Communications

Annmarie Dadoly,
Editor

Joseph O’Riordan,
Writer

Kristin Edmonston,
Production Coordinator